# Mebendazole in Newly Diagnosed High-Grade Glioma Patients Receiving Temozolomide

> **NCT01729260** · PHASE1 · COMPLETED · sponsor: **Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins** · enrollment: 24 (actual)

## Conditions studied

- Newly Diagnosed High-Grade Glioma

## Interventions

- **DRUG:** Mebendazole

## Key facts

- **NCT ID:** NCT01729260
- **Lead sponsor:** Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-04-04
- **Primary completion:** 2016-09
- **Final completion:** 2021-04-16
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2021-05-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01729260

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01729260, "Mebendazole in Newly Diagnosed High-Grade Glioma Patients Receiving Temozolomide". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01729260. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*